Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2

Similar Items

• Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
  od: Tai, Wanbo, i dr.
  Izdano: (2020)
• The spike protein of SARS-CoV — a target for vaccine and therapeutic development
  od: Du, Lanying, i dr.
  Izdano: (2009)
• Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
  od: Du, Lanying, i dr.
  Izdano: (2013)
• Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2
  od: Jiang, Shibo, i dr.
  Izdano: (2020)
• Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
  od: Jiang, Shibo, i dr.
  Izdano: (2020)